ERBB4 Mutant Alleles May Drive *BRAF* WT Melanomas

Lauren M. Lucas[1], Richard L. Cullum[1,2], Jessica A. Markham[1], Joelle N. Woggerman[1,3], Vipasha Dwivedi[1], Rania H. Mohamedelhassan[1], Laura J. Cook[1,4], Connor M. Kelley[1], Elizabeth L. Knerr[1,4], David P. Kaufmann[1], Megan A. Jacobi[1,4], Darby C. Taylor[1,4], Cristina C. Rael[1,4], Damien S. Waits[4], Taraswi M. Ghosh[1], Kenneth M. Halanych[4,5], Ram B. Gupta[2,6], and David J. Riese II[1,7#]

[1]Department of Drug Discovery and Development, Auburn University, Auburn, AL 36849 USA
[2]Department of Chemical Engineering, Auburn University, Auburn, AL 36849 USA
[3]Department of Chemistry and Biochemistry, Auburn University, Auburn, AL 36849 USA
[4]Department of Biological Sciences, Auburn University, Auburn, AL 36849 USA
[5]Center for Marine Science, University of North Carolina-Wilmington, Wilmington, NC 28403 USA
[6]Department of Chemical and Life Science Engineering, Virginia Commonwealth University, Richmond, VA 23284
[7]O'Neal Comprehensive Cancer Center, The University of Alabama at Birmingham, Birmingham, AL 35233 USA

[#]Corresponding Author
Department of Drug Discovery and Development
Auburn University Harrison College of Pharmacy
Walker 3211G
Auburn, AL 36849, USA
driese@auburn.edu
334-844-8358

Abstract

Metastatic skin cutaneous melanomas that contain wild-type *BRAF* alleles ("*BRAF* WT melanomas") remain a significant clinical challenge, primarily because of the paucity of targets for therapeutic intervention. In prior work, *in silico* analyses of The Cancer Genome Atlas Skin Cutaneous Melanoma (TCGA-SKCM) dataset suggested that elevated transcription of the gene that encodes the ERBB4 receptor tyrosine kinase may drive *BRAF* WT melanomas. Moreover, that prior work demonstrated that expression of the wild-type ERBB4 gene (WT *ERBB4*) stimulates clonogenic proliferation by the MEL-JUSO, MeWo, and IPC-298 human *BRAF* WT melanoma cell lines. Moreover, expression of a dominant-negative (K751M) *ERBB4* mutant (*ERBB4* DN) inhibits clonogenic proliferation by the MEL-JUSO and MeWo cell lines.

Here we have extended these findings by investigating the role of ERBB4 mutant alleles in *BRAF* WT melanomas. *In silico* analyses of the TCGA-SKCM *BRAF* WT melanoma dataset indicates that *ERBB4* missense mutant alleles occur in a non-random manner, suggesting that melanomagenesis selects for the *ERBB4* missense mutant alleles. Specifically, *ERBB4* missense mutant alleles affect amino acid residues that are weakly correlated with residues conserved in the ERBB3 extracellular domains and the EGFR tyrosine kinase domain. The occurrence of *ERBB4* missense mutant alleles in the TCGA-SKCM *BRAF* WT melanoma dataset is weakly inversely correlated with events that cause ERBB4-independent PI3K pathway signaling and is strongly correlated with events that cause elevated RAS pathway signaling. Thus, the *in silico* analyses suggest that *ERBB4* mutant alleles stimulate PI3K signaling, which cooperates with elevated RAS signaling to drive *BRAF* WT melanomas. Moreover, the *in silico* analyses have prioritized the *ERBB4* mutant alleles as candidate drivers of *BRAF* WT melanomas. One of the prioritized *ERBB4* mutant alleles (P759L) stimulates greater clonogenic proliferation of MEL-JUSO cells than does WT *ERBB4*. Thus, our *in silico* prioritization strategy may effectively identify *ERBB4* mutants that drive *BRAF* WT melanomas. Finally, the results of our *in silico* analyses suggest that ERBB4-dependent, BRAF WT melanomas may be effectively treated by a combination of a PI3K pathway inhibitor and a RAS pathway inhibitor.

Introduction

BRAF inhibitors, MEK inhibitors, and immune checkpoint inhibitors ("checkpoint inhibitors") are transforming the treatment of advanced skin cutaneous melanomas that possess oncogenic *BRAF* mutations ("*BRAF* mutant melanomas"). The Surveillance, Epidemiology, and End Results Program of the National Cancer Institute [1] reports a 25% five-year survival of metastatic skin cutaneous melanoma patients for the period of 2010 to 2018 [2]. In contrast, a 2019 clinical trial reports 34% five-year survival of patients with advanced *BRAF* mutant skin cutaneous melanomas treated with BRAF and MEK inhibitors [3, 4]. A 2019 clinical trial reports 60% five-year survival of patients with advanced *BRAF* V600X mutant skin cutaneous melanomas *("BRAF* V600X mutant melanomas") treated with a combination of immune checkpoint inhibitors [3, 5]. Finally, combining immune checkpoint inhibitors with BRAF and MEK inhibitors will likely lead to further improvements in survival [6].

Unfortunately, approximately 50% of advanced skin cutaneous melanomas possess wild-type *BRAF* alleles, and contemporary treatments of advanced skin cutaneous melanomas that contain wild-type *BRAF* ("*BRAF* WT melanomas") have yielded less impressive results. In part, these less impressive results are because of a paucity of actionable targets for the (targeted) treatment of these tumors [7]. Moreover, the five-year survival of patients with advanced *BRAF* WT skin cutaneous melanomas treated with immune checkpoint inhibitors is only 48%, less than the 60% experienced by patients with advanced *BRAF* mutant skin cutaneous melanomas in a parallel study [5]. Hence, our previous work has attempted to address this gap in treatment efficacy by evaluating the ERBB4 receptor tyrosine kinase as a candidate target in *BRAF* WT skin cutaneous melanomas [8].

ERBB4 (HER4) is a member of the ERBB family of receptor tyrosine kinases (RTKs), which includes the epidermal growth factor receptor (EGFR), ERBB2 (HER2/Neu), and ERBB3 (HER3). ERBB4 possesses extracellular ligand-binding domains, a single-pass hydrophobic transmembrane domain, an intracellular tyrosine kinase domain, and intracellular tyrosine residues that function as phosphorylation sites (Figure 1). Ligand binding to EGFR, ERBB3, or ERBB4 stabilizes the receptor extracellular domains in an open conformation competent for symmetrical homodimerization and heterodimerization of the receptor extracellular domains. The dimerization of the extracellular domains enables asymmetrical dimerization of the receptor cytoplasmic domains. Phosphorylation of one receptor monomer on tyrosine residues by the tyrosine kinase domain of the other receptor monomer ("cross-phosphorylation") ensues (Figure 2). This tyrosine phosphorylation creates binding sites for effector proteins and activation of downstream signaling pathways [9].

Elevated signaling by an RTK is a hallmark of many types of cancer. Hence, RTK overexpression, ligand overexpression, and gain-of-function mutations in an RTK gene are all mechanisms for pathologic, elevated RTK signaling [10]. Indeed, EGFR and ERBB2 have been validated as targets for therapeutic intervention in numerous types of tumors; monoclonal antibodies and small molecular tyrosine kinase inhibitors have been approved to treat tumors dependent on these receptors [11-26]. It appears that ERBB3, particularly ERBB3-ERBB2 heterodimers, also drives various human tumors [27, 28].

In contrast, the role that ERBB4 plays in human tumors remains ambiguous. Part of the ambiguity reflects that an ERBB4 homodimer can function as a tumor suppressor, whereas an ERBB4-EGFR or ERBB4-ERBB2 heterodimer can drive tumor cell proliferation or aggressiveness [9]. Our previous work has demonstrated that ectopic expression of wild-type *ERBB4* stimulates the proliferation of *BRAF* WT melanoma cell lines and ectopic expression of a dominant-negative (K751M) mutant *ERBB4* allele inhibits the proliferation of *BRAF* WT melanoma cell lines. These data suggest that *ERBB4* is a driver of *BRAF* WT melanomas [8].

Structural studies of ERBB family receptors and analyses of *ERBB* mutant alleles has revealed multiple mechanisms by which a missense mutation in an *ERBB* gene may cause elevated (oncogenic) signaling by that receptor protein [29]. (1) A mutation may increase the affinity of a receptor for its cognate ligands. (2) A mutation may cause a shift in the extracellular domain conformational equilibrium; the mutant may now favor the open conformation, which is competent for dimerization and signaling, over the closed conformation, which is not competent for dimerization and signaling. (3) A mutation may directly increase receptor dimerization, through the creation of novel intermolecular chemical bonds. Such activating mutations may affect dimerization of the extracellular domains, transmembrane domain, or intracellular kinase domain. (4) A mutation may destabilize the inactive conformation of the kinase domain or stabilize the active conformation of the kinase domain. (5) The substitution of a glutamate residue for a tyrosine residue at the site of tyrosine phosphorylation may mimic phosphorylation, resulting in constitutive binding of effector proteins and activation of downstream signaling events.

We have observed that ERBB4 appears to function as a driver of proliferation in multiple *BRAF* WT melanoma cell lines [8]. Moreover, *ERBB4* mutant alleles, most of which remain largely uncharacterized, have been found in several cancers, including melanomas [9]. Thus, here we test the hypothesis that *ERBB4* mutant alleles found in *BRAF* WT melanoma samples function as drivers in *BRAF* WT melanoma cell lines.

Results

A. ERBB4 non-synonymous mutations occur at a non-stochastic frequency. Our in silico analysis of ERBB4 mutant alleles is based on The Cancer Genome Atlas Skin Cutaneous Melanoma (TCGA-SKCM) dataset (470 cases) [30]. Most of the analyses reported here focus on the 227 cases that possess wild-type (WT) BRAF alleles ("*BRAF* WT melanomas") [8, 30].

In the TCGA-SKCM dataset, *ERBB4* missense mutant alleles are slightly more common in *BRAF* WT melanomas than *BRAF* V600X mutant melanomas (15.4% and 11.4% respectively). Therefore, we hypothesized that *ERBB4* mutant alleles are selected in *BRAF* WT melanomas, thereby justifying the analyses reported in this work.

The ratio of non-synonymous (missense, stop gained, frame shift) to synonymous (synonymous, stop retained) mutations is an indicator of selection for mutant alleles by tumor cells. Generally speaking, if the ratio of non-synonymous to synonymous mutant alleles (N/S ratio) in a particular gene is greater than 1, it is indicative of selection for non-synonymous mutant alleles in that gene [31].

Because of the exposure of skin cells to ultraviolet (UV) light, melanomas carry numerous cytosine to thymine mutations, many of which function as passengers. This precludes using an N/S cutoff of 1 to identify genes for which mutant alleles function as drivers [32]. Thus, we have compared the N/S ratio for *ERBB4* in the 227 *BRAF* WT melanomas of the TCGA-SKCM dataset against the N/S ratio for genes (*ARMC4, CFTR, ERC2, SLIT2,* and *SLIT3)* that are roughly the same size as *ERBB4* and that from the literature do not appear to function as melanoma drivers.

The N/S ratio for *ERBB4* is 5.33, which is significantly greater ($p=0.003$) than the average N/S ratio for the five control genes (2.44) **(Table 1)**. Moreover, the N/S ratio for the *KRAS* and *NRAS* oncogenes and the *CDKN2A*, *NF1*, *RB*, and *TP53* tumor suppressor genes is also greater than the average N/S ratio for the five control genes. In contrast, the N/S ratio for EGFR, ERBB2, and ERBB3 genes is not significantly greater than the average N/S ratio for the five control genes. These results suggest that mutations in *ERBB4*, but not mutations in *EGFR*, *ERBB2*, or *ERBB3*, function as drivers in *BRAF* WT melanomas.

B. ERBB4 mutations are somewhat more likely to affect functionally conserved amino acid residues. Using the TCGA-SKCM, *BRAF* WT melanoma dataset, we identified 40 *ERBB4* missense mutations that are not coincident with an *ERBB4* stop-gained mutation or splice site mutation; one of these *ERBB4* mutant alleles was found in three tumor samples and the other 39 *ERBB4* mutant alleles were found in a single tumor sample **(Figure 3).** Therefore, there is only a single, weak mutational hotspot and we must employ other approaches to identify and prioritize candidate driver mutations.

The conservation of a particular amino acid residue across functionally related proteins suggests that residue is critical for the shared function of the related proteins. Thus, we hypothesized that *ERBB4* melanoma driver mutations are more likely to affect conserved residues.

Many members of the epidermal growth factor family of peptide hormones bind to both ERBB3 and ERBB4 **(Figure 2)** [33]. Moreover, ERBB3 dimerization and ERBB4 dimerization are regulated by an identical mechanism **(Figure 1)** [9]. We have identified fifteen ERBB4 extracellular domain (ECD) I-IV amino acid residues that are affected by *ERBB4* missense mutations found in the TCGA-SKCM *BRAF* WT melanoma data set. We hypothesized that these fifteen residues correlated with ERBB4 residues that are conserved in the ERBB3 ECDs I-IV. However, only eleven residues affected by *ERBB4 BRAF* WT melanoma missense mutations are conserved in the ERBB3 ECDs I-IV, which falls well short of a statistically significant correlation (p=0.3763) **(Table 2a).** Nonetheless, these eleven *ERBB4* missense mutant alleles (G85S, R106C, R196C, P331S, G340E, A383T, S418F, T422I, E452K, R491K, and P517A) are assigned a priority point to help identify the best candidates for *ERBB4* driver mutant alleles in *BRAF* WT melanomas.

Only ERBB4 and EGFR directly bind ligands and form homodimers that undergo ligand-dependent receptor cross-phosphorylation [33]. (ERBB2 does not bind ligand and ERBB3 lacks sufficient kinase activity.). We have identified thirteen ERBB4 tyrosine kinase domain amino acid residues that are affected by *ERBB4* missense mutations found in the TCGA-SKCM *BRAF* WT melanoma data set. We hypothesized that these thirteen residues correlated with ERBB4 residues that are conserved in the EGFR tyrosine kinase domain. Indeed, all thirteen residues affected by *ERBB4 BRAF* WT melanoma missense mutations are conserved in the EGFR tyrosine kinase domain. However, this distribution falls just short (p=0.0565) of a statistically significant correlation **(Table 2b).** Nonetheless, these thirteen *ERBB4* missense mutant alleles (R711C, G741E, P759L, P800L, D813N, N814T, D861N, L864P, P925S, G936E, P943S, E969K, and R992C) are assigned a priority point to help identify the best candidates for *ERBB4* driver mutant alleles in *BRAF* WT melanomas.

Finally, three *ERBB4* missense mutant alleles (R106C, G741E, L864P) found in the TCGA-SKCM *BRAF* WT melanoma data set correspond to gain-of-function alleles in *EGFR* (R108K, G735S, and L858R, respectively) or *ERBB2* (L866M corresponds to *ERBB4* L864P). As a result, these three *ERBB4* missense alleles **(Table 3)** are assigned a priority point to help identify the best candidates for *ERBB4* driver mutant alleles in *BRAF* WT melanomas.

C. ERBB4 missense mutants are somewhat less common in TCGA-SKCM BRAF WT melanoma cases in which there are PI3K or PTEN alterations that are predicted to stimulate the PI3K pathway. The PI3K pathway is required for ERBB4-EGFR heterodimers to stimulate IL3-independent proliferation of BaF3 mouse lymphoid cells [34]. Likewise, an *ERBB4* gain-of-function mutant allele causes increased AKT phosphorylation in a human melanoma cell line [35]. Thus, we postulated that *ERBB4* driver mutants in BRAF WT melanomas stimulate PI3K pathway signaling and are inversely correlated with events (increased *PIK3CA* transcription, gain-of-function mutation in *PIK3CA*, decreased *PTEN* transcription, or loss-of-function mutation in *PTEN*) that would cause ERBB4-independent increases in PI3K pathway signaling. Twenty-nine cases in the TCGA-SKCM *BRAF* WT melanoma dataset contain an *ERBB4* missense mutation, but no *PIK3CA* mutation or increase in *PIK3CA* transcription, nor any *PTEN* mutation or decrease in *PTEN* transcription. However, this distribution falls just short (p=0.068) of a

statistically significant correlation (Table 4). Nonetheless, the 36 *ERBB4* mutant alleles (E33K, G85S, R106C, R114Q, D150N, R196C, P331S, A383T, S418F, T422I, E452K, R491K, P517A, G549S, P572L, R711C, G741E, P759L, P800L, D813N, N814T, D861N, P925S, G936E, P943S, E969K, R992C, P1080L, P1117L, R1127K, R1139Q, R1142Q, P1165L, P1276S, P1282S, and P1300S) found in these 29 cases are assigned a priority point to help identify the best candidates for *ERBB4* driver mutant alleles in *BRAF* WT melanomas.

D. ERBB4 missense mutants are significantly more common in TCGA-SKCM BRAF WT melanoma cases in which there are RAS or NF1 nonsynonymous mutations. Gain-of-function *RAS* gene mutations occur in about 30% of skin cutaneous melanomas, and loss-of-function mutations in *NF1* occur in about 20% of skin cutaneous melanomas. Moreover, gain-of-function *BRAF* mutations, gain-of-function *RAS* gene mutations, and loss-of-function *NF1* mutations are largely mutually exclusive in skin cutaneous melanomas [36].

Receptor tyrosine kinases typically stimulate RAS pathway signaling [37-43]. Hence, in the *BRAF* WT melanomas of the TCGA-SKCM dataset, we predicted that cases that contain an ERBB4 missense mutation would be less likely to contain a nonsynonymous mutation in a *RAS* gene or *NF1*. Surprisingly, 29 cases in the TCGA-SKCM *BRAF* WT melanoma dataset contain an *ERBB4* missense mutation, as well as a nonsynonymous mutation in a *RAS* gene or *NF1* (Table 5). This statistically significant correlation (p=0.0189) suggests that ERBB4 signaling cooperates with RAS signaling to drive *BRAF* WT melanomas. Hence, we have assigned a priority point to the 33 *ERBB4* mutant alleles (E33K, G85S, R106C, D150N, P331S, A383T, S418F, T422I, E452K, R491K, P517A, G549S, P572L, F662L, R711C, P759L, P800L, D813N, D861N, P925S, G936E, E969K, R992C, P1080L, P1117L, R1127K, R1139Q, R1142Q, P1165L, E1187D, P1276S, P1282S, and P1300S) found in the 29 cases that contain a nonsynonymous mutation in a *RAS* gene or *NF1*.

E. ERBB4 missense mutations are significantly more likely in cases where there is a RAS or NF1 nonsynonymous mutation as well as no other apparent cause of increased PI3K signaling. Our *in silico* analyses lead us to hypothesize that gain-of-function *ERBB4* mutants stimulate signaling by the PI3K pathway and that this PI3K signaling cooperates with elevated RAS signaling (caused by a gain-of-function *RAS* gene mutation or a loss-of-function *NF1* mutation) to drive *BRAF* WT melanomas. Thus, we tested whether *ERBB4* missense mutations are more likely to occur in cases where there is a *RAS* gene or *NF1* mutation and NO events (increases in *PIK3CA* transcription, gain-of-function mutations in *PIK3CA*, decreases in *PTEN* transcription, or loss-of-function mutations in *PTEN*) that would cause ERBB4-independent increases in PI3K pathway signaling **(Table 6)**. Twenty-five cases in the TCGA-SKCM *BRAF* WT melanoma dataset contain an *ERBB4* missense mutation, as well as a nonsynonymous mutation in a *RAS* gene or *NF1*, but no event (increases in *PIK3CA* transcription, gain-of-function mutations in *PIK3CA*, decreases in *PTEN* transcription, or loss-of-function mutations in *PTEN*) that would cause ERBB4-independent increases in PI3K pathway signaling. This statistically-significant correlation (p=0.0166) supports our hypothesis. However, because the 31 *ERBB4*

mutant alleles found in these 25 cases received a priority point(s) through the results of Table 4 and Table 5, we have not assigned any priority points based on the data from Table 6.

F. ERBB4 mutations and elevated ERBB4 transcription appear to independently drive BRAF WT melanomas. *In silico* analyses of the TCGA-SKCM *BRAF* WT melanoma dataset suggest that elevated *ERBB4* transcription appears to cooperate with elevated RAS signaling (due to a gain-of-function *RAS* gene mutation or a loss-of-function *NF1* mutation) to drive *BRAF* WT melanomas [8]. Thus, it is possible that *ERBB4* mutant alleles require elevated *ERBB4* transcription to drive *BRAF* WT melanomas. We have identified 129 cases in the TCGA-SKCM *BRAF* WT melanoma dataset that contain a non-synonymous *RAS* or *NF1* mutation and for which *ERBB4* transcription data is available. Twenty of these cases contain an *ERBB4* missense mutation, eighteen cases exhibit elevated *ERBB4* transcription, and three cases contain an *ERBB4* missense mutation and exhibit elevated *ERBB4* transcription **(Figure 4)**. These data suggest that *ERBB4* mutations and elevated *ERBB4* transcription appear to independently drive *BRAF* WT melanomas. Hence, the 29 *ERBB4* mutants (E33K, R106C, R114Q, D150N, R196C, G340E, A383T, S418F, E452K, R491K, P517A, G549S, F662L, R711C, P759L, P800L, D813N, N814T, D861N, L864P, P925S, G936E, P943S, E969K, R1142Q, P1165L, P1276S, P1282S, P1300S) found in the twenty cases that contain an *ERBB4* missense allele are assigned a priority point to help identify the best candidates for *ERBB4* driver mutant alleles in *BRAF* WT melanomas.

G. We have prioritized ERBB4 mutant alleles as candidate drivers of BRAF WT melanomas. Based on the *in silico* data presented in **Table 2a**, **Table 2b**, **Table 3**, **Table 4**, **Table 5**, and **Figure 4**, we have established and applied criteria for prioritizing *ERBB4* mutant alleles as candidate drivers of *BRAF* WT melanomas **(Table 7).** Next, we will describe our efforts to determine whether prioritized *ERBB4* mutant alleles function as drivers of *BRAF* WT melanomas.

H. A prioritized ERBB4 mutant allele stimulates clonogenic proliferation of a BRAF WT melanoma cell line. We have shown that ectopic expression of wild-type *ERBB4* (*ERBB4* WT) significantly stimulates the clonogenic proliferation of MEL-JUSO, MeWo, and IPC-298 human *BRAF* WT melanoma cell lines [8]. Moreover, ectopic expression of the dominant-negative (K751M) *ERBB4* (*ERBB4* DN) mutant significantly inhibits the clonogenic proliferation of MEL-JUSO and MeWo cell lines and modestly inhibits the clonogenic proliferation of IPC-298 cells. These results indicate that *ERBB4* is both sufficient and necessary to drive some *BRAF* WT melanoma cell lines; they also suggest that we can use the MEL-JUSO, MeWo, and IPC-298 cell lines to identify *ERBB4* mutant alleles that function as *bona fide* drivers of *BRAF* WT melanomas.

We have tested whether the high priority R106C and P759L *ERBB4* mutants (Table 7) stimulate a greater amount of clonogenic proliferation than *ERBB4* WT. As a positive control, we tested the Y285C *ERBB4* mutant, which was found in non-small cell lung carcinoma samples and stimulates ligand-dependent and -independent ERBB4 signaling and increased ERBB4

heterodimerization with ERBB2 [9, 44]. In the MEL-JUSO cells, the ERBB4 P759L and Y295C mutants caused greater clonogenic proliferation of the BRAF than ERBB4 WT. In contrast, the ERBB4 R106C and ERBB4 WT caused a similar level of clonogenic proliferation (Table 8). These data suggest that the *ERBB4* P759L mutant may be a *bona fide* driver of BRAF WT melanomas.

I. A heterologous model system can be used to determine whether ERBB4 mutants that stimulate the proliferation of BRAF WT melanomas exhibit elevated ligand-dependent or ligand-independent ERBB4 signaling activity. The MEL-JUSO, MeWo, and IPC-298 cell lines exhibit endogenous expression of ERBB4 ligands [8]. Thus, *ERBB4* mutants could stimulate clonogenic proliferation of these cell lines via a ligand-dependent or ligand-independent mechanism.

We and others have previously demonstrated that ERBB4 homodimers typically do not stimulate cell proliferation, whereas ERBB4-ERBB2 and ERBB4-EGFR heterodimers do stimulate cell proliferation. Indeed, ERBB4 ligands do not stimulate proliferation of BaF3 mouse lymphoid cells engineered to express ERBB4 but do stimulate proliferation of BaF3 cells engineered to express ERBB4 and EGFR or ERBB4 and ERBB2 [9]. BaF3 cells lack endogenous EGFR, ERBB2, and ERBB4 expression. But, because they endogenously express ERBB3, they are not ideal for studying the functional differences among ERBB4 homodimers, ERBB4-EGFR heterodimers, or ERBB4-ERBB2 heterodimers [45].

Thus, we have chosen to study these functional differences using derivatives of the 32D mouse lymphoid cell line, which lack endogenous expression of all four ERBB family receptors and are dependent on interleukin 3 (IL3) for their proliferation [46]. 32D cells were generated that express both ERBB4 and ERBB2, ERBB4 alone, ERBB2 alone, and the appropriate vector controls. None of these 32D cell lines exhibit proliferation in the absence of both IL3 and an ERBB4 ligand. Moreover, the ERBB4 ligand NRG1beta stimulates IL3-independent proliferation of the 32D/ERBB2+ERBB4 cells but does not stimulate IL3-independent proliferation of any of the other 32D cell lines (Table 9). Thus, 32D cell lines that co-express ERBB4 mutants and ERBB2 are ideal for studying whether these ERBB4 mutants potentiate the effects of ERBB4 ligands or enable ERBB4 coupling to proliferation independent of an ERBB4 ligand.

Materials and Methods

Analysis of the TCGA-SKCM dataset:
Clinical and biospecimen data were downloaded for all 470 cases found in the TCGA-SKCM dataset [47]. All analyzed datasets are publicly available through the NIH/NCI Genomic Data Commons (GDC) portal [48]. The R statistical computing and graphics environment software [49] was used to reorganize the dataset. Statistical analyses were performed using GraphPad Prism [50].

Creating *BRAF* WT dataset:
All *BRAF* WT cases were segregated from the TCGA-SKCM dataset for analysis. Cases in which there were ERBB4 mutation(s) which co-occurred with a stop gained or splice-site mutation were removed from the *BRAF* WT dataset for analysis of the effect of *ERBB4* missense mutation in *BRAF* WT melanoma (Sections IIIB-F). Three mutations fell into this category (M958I, R47Q, G573D). These mutations and the stop gained mutated cases are included in the analysis for section IIIA.

Cell Lines and cell culture:
Mouse C127 fibroblasts and the ψ2 and PA317 recombinant retrovirus packaging cell lines are generous gifts of Daniel DiMaio (Yale University). These cells were cultured essentially as described previously [51]. The MEL-JUSO [52] human melanoma cell line was obtained from DSMZ [53] (Braunschweig, Germany) and was cultured as recommended. The 32D mouse myeloid cell line has been described previously and was cultured as recommended [54]. Cell culture media, serum, and supplements were obtained from Cytiva [55] (Marlborough, VA). G418 was obtained from Corning [56] (Corning, NY). Genetic and mRNA expression data for the MEL-JUSO cell line were obtained from the Broad Institute Cancer Cell Line Encyclopedia (CCLE) [57].

Mutagenesis of DNA Constructs:
The recombinant retroviral expression construct pLXSN-ERBB4 has been described previously [45]. We used pLXSN-ERBB4 as the parent plasmid for site-directed mutagenesis using the Q5 Site Directed Mutagenesis Kit (NEB). Mutagenesis was performed essentially as recommended by the manufacturer.

Recombinant retroviruses:
Briefly, the recombinant amphotropic retroviruses LXSN, LXSN-ERBB4 (ERBB4 WT), LXSN-ERBB4 R106C, LXSN-ERBB4 Y285C, and LXSN-ERBB4 P759L were packaged using the ψ2 ecotropic retrovirus packaging cell line, and the PA317 amphotropic retrovirus packaging cell line as previously described [45, 58, 59]. 32D cells were infected with the recombinant amphotropic retroviruses LXSN, LXSN-ERBB4, LXSN-HygR, and LXSN-HygR-ERBB2 at a 0.1 multiplicity of infection. These constructs have been previously described [46, 51].

Clonogenic Proliferation Assay:
C127, MEL-JUSO cells were infected with 500 and 3000 amphotropic retroviral infectious units (respectively), essentially as described earlier. After incubation with the viruses, infected cells were selected using G418 at a concentration of 800 ug/mL. The resulting colonies of G418-resistant cells were stained using Giemsa 8 and 13 days later (respectively), and colonies were counted. C127 infections served as a control for viral titer. Tissue culture plates were digitized, and clonogenic proliferation efficiency was calculated as previously described [58]. The statistical significance of differences in clonogenic proliferation was calculated using ANOVA with a p-value threshold of <0.05 (1-tailed).

Stimulation of ERBB4-ERBB2 heterodimer dependent proliferation in 32D cells:
32D cells which stably express ERBB4, ERBB2, or ERBB4 and ERBB2 were treated with and without 30nM of NRG1β (Recombinant Human Heregulinβ-1, Peprotech) in the absence of IL3. After six days cells were counted using a hemacytometer to evaluate NRG1β-dependent growth.

Discussion

A. The apparent selection for ERBB4 mutant alleles in the TCGA-SKCM BRAF WT melanoma data set enables prioritization of individual ERBB4 mutant alleles. Previous *in silico* analyses of the TCGA-SKCM BRAF WT melanoma dataset suggest that elevated *ERBB4* transcription drives the proliferation of *BRAF* WT melanomas [8]. In this work we show that *in silico* analyses of *ERBB4* mutant alleles found in the TCGA-SKCM *BRAF* WT melanoma data set suggest that *ERBB4* mutant alleles may drive the proliferation of *BRAF* WT melanomas.

B. An ERBB4 mutant allele that is a candidate driver of BRAF WT melanomas does in fact drive the proliferation of BRAF WT melanoma cell lines. This work has identified the *ERBB4* R106C and P759L mutants as high-priority candidate drivers of *BRAF* WT melanomas. We have previously demonstrated that WT *ERBB4* stimulates the clonogenic proliferation of the MEL-JUSO, IPC-298, and MeWo human *BRAF* WT melanoma cell lines [8]. Thus, we can use these cell lines to compare the biological activity of candidate *BRAF* WT melanoma driver mutants of *ERBB4* against WT *ERBB4*.

The *ERBB4* P759L mutant stimulates a greater amount of clonogenic proliferation of the MEL-JUSO *BRAF* WT melanoma cell line than WT *ERBB4*. In contrast, the *ERBB*4 R106C mutant and WT *ERBB4* stimulate similar amounts of clonogenic proliferation of the MEL-JUSO *BRAF* WT melanoma cell line. It is possible that the *ERBB4* R106C and P759L mutants will both stimulate greater clonogenic proliferation of the IPC-298 and MeWo cell lines than WT *ERBB4*. If so, we can use the IPC-298 and MeWo cell lines to explore the mechanisms by which the *ERBB4* R106C and P759L mutants functionally differ. Those and other mechanistic insights will undoubtedly improve the *in silico* strategy used to identify *ERBB4* mutants that are high priority candidate *BRAF* WT melanoma drivers.

C. 32D/ERBB4+ERBB2 and control cell lines are suitable for determining the mechanisms by which ERBB4 gain-of-function mutants stimulate cell proliferation. Here we demonstrate that ligand-induced homodimers of WT ERBB4 do not cause IL3 independence in 32D cells. In contrast, ligand-induced heterodimers of ERBB2 and WT ERBB4 do cause IL3 independence. Thus, we can use this model system to determine whether *ERBB4* gain-of-function mutants cause increased ligand-dependent or -independent signaling. We can also determine whether the effects of gain-of-function *ERBB4* mutants are absolutely dependent on heterodimerization or whether gain-of-function *ERBB4* mutants enable ERBB4 homodimers to stimulate IL3 independence. Finally, we can use analogous 32D/ERBB4+EGFR cell lines to determine whether the biological effects of ERBB4 gain-of-function mutants are mediated by both ERBB4-ERBB2 and ERBB4-EGFR heterodimers.

D. Our in silico analyses suggest strategies for treating ERBB4-dependent, BRAF WT melanomas. Here we demonstrate that, in the TCGA-SKCM *BRAF* WT melanoma dataset, *ERBB4* mutants are correlated with nonsynonymous mutations in a *RAS* gene or *NF1*. This

surprising observation suggests that ERBB4 does not stimulate RAS signaling in *BRAF* WT melanomas. Instead, it appears that ERBB4 signaling cooperates with RAS signaling to drive *BRAF* WT melanomas.

We have previously demonstrated that the PI3K pathway is required for ERBB4-EGFR heterodimers to stimulate IL3 independent proliferation of BaF3 cells [34]. Likewise, a gain-of-function *ERBB4* mutant stimulates AKT phosphorylation in a human melanoma cell line [35]. Here we demonstrate that, in the TCGA-SKCM BRAF WT melanoma dataset, *ERBB4* mutations are somewhat inversely correlated with events predicted to cause ERBB4-independent activation of the PI3K pathway (mutation of *PIK3CA*, increased *PIK3CA* transcription, mutation of *PTEN*, or decrease in *PTEN* transcription). Thus, we have postulated that, in *BRAF* WT melanomas, *ERBB4* gain-of-function mutants stimulate PI3K signaling, which cooperates with elevated RAS signaling to drive the proliferation of these tumor cells.

Hence, we postulate that a suitable treatment for ERBB4-dependent, *BRAF* WT tumors would consist of a combination of a RAS pathway inhibitor and a PI3K pathway inhibitor. We believe that the most suitable RAS pathway inhibitor would be a MEK inhibitor (trametinib, binimetinib, selumetinib, or cobimetinib). The toxicity of the PI3K and mTOR inhibitors (alpelisib, sirolimus, everolimus, temsirolimus) may preclude the use of these drugs in this application. However, no specific ERBB4 inhibitors have been approved by the FDA. However, because ERBB4 mutants are likely to drive BRAF WT melanomas through signaling by ERBB4-EGFR or ERBB4-ERBB2 heterodimers, anti-EGFR drugs (gefitinib or cetuximab) or anti-ERBB2 drugs (lapatinib or pertuxumab) may be suitable. Future work is needed to evaluate these agents.

Tables

	Non-synonymous	Synonymous	N/S Ratio	
			Mean	Std Dev
Control Genes			2.44	1.23
ARMC4	60	13	4.62	
CFTR	37	18	2.06	
ERC2	53	28	1.89	
SLIT2	50	26	1.92	
SLIT3	49	29	1.69	
ERBB4 Gene			**N/S Ratio**	**One Sample T-test Against Control Genes**
ERBB4	48	9	5.33	p = 0.003
Oncogenes			**N/S Ratio**	
KRAS	12	1	12.00	
NRAS	126	1	126.00	
Tumor Suppressor Genes			**N/S Ratio**	
CDKN2A	25	6	4.17	
NF1	59	15	3.93	
RB1	13	2	6.50	
TP53	35	3	11.67	
ERBB1-3 Genes			**N/S Ratio**	
EGFR	25	10	2.50	
ERBB2	5	2	2.50	
ERBB3	6	5	1.20	

Table 1. The ratio of *ERBB4* nonsynonymous to synonymous (N/S) mutations in the TCGA-SKCM *BRAF* WT melanoma dataset suggests that *ERBB4* nonsynonymous mutations function as drivers of *BRAF* WT melanomas.

TCGA-SKCM, *BRAF* WT, ERBB4 ECDs 1-4

	Site of *ERBB4* Mutation	Not Site of *ERBB4* Mutation	Total
Conserved in ERBB3 ECDs	11	351	362
Not Conserved in ERBB3 ECDs	4	214	218
Total	15	565	580

p = 0.3763

Table 2a. *ERBB4* missense mutations that affect residues of the extracellular domains (ECDs) are slightly correlated with residues that are conserved in the ERBB3 extracellular domains.

TCGA-SKCM, *BRAF* WT, ERBB4 Kinase Domain

	Site of *ERBB4* Mutation	Not Site of *ERBB4* Mutation	Total
Conserved in EGFR kinase domain	13	226	239
Not Conserved in EGFR kinase domain	0	64	64
Total	13	290	303

p = 0.0565

Table 2b. *ERBB4* missense mutations that affect residues of the kinase domain are somewhat correlated with residues that that are conserved in the EGFR kinase domain.

***ERBB4* Mutation**	**Corresponding Mutation in *EGFR***	**Corresponding Mutation in *ERBB2***	**Function**
R106C	R108K		Gain-of-function Oncogenic
G741E	G735S		Gain-of-function Oncogenic
L864P	L858R	L866M	Gain-of-function Oncogenic

Table 3. Three *ERBB4* missense mutations occur at residues that correspond to sites of oncogenic mutations in *EGFR* or *ERBB2.*

	***ERBB4* Missense Mutation**	***ERBB4* WT**	**Total**
Mutation or Increase in PIK3CA Expression or Mutation or Decrease in PTEN Expression	4	51	55
No Mutation or Increase in PIK3CA Expression and no Mutation or Decrease in PTEN Expression	29	138	167
Total	33	189	222

p = 0.068

Table 4. *ERBB4* missense mutants are somewhat inversely correlated with events (mutation of *PIK3CA*, increased *PIK3CA* transcription, mutation of *PTEN*, or decrease in *PTEN* transcription) predicted to result in increased PI3K pathway signaling activity.

	ERBB4 Missense Mutation	ERBB4 WT	Total
RAS or NF1 Nonsynonymous Mutation	29	128	157
RAS and NF1 WT	4	61	65
Total	33	189	222

p = 0.0189

Table 5. *ERBB4* missense mutations are significantly correlated with a *RAS* or *NF1* nonsynonymous mutation.

		ERBB4 Missense Mutation	*ERBB4* WT	Totals
RAS or *NF1* Mutation	*PIK3CA* Mutation or Increase in PIK3CA Expression or *PTEN* Mutation or Decrease in PTEN Expression	4	35	39
	No *PIK3CA* Mutation or Increase in PIK3CA Expression and no *PTEN* Mutation or Decrease in PTEN Expression	25	93	118
RAS and *NF1* WT	No Consideration of *PIK3CA* /*PTEN* Mutation/Expression Status	4	61	65
Totals		33	189	222

p = 0.016

Table 6. ERBB4 missense mutations are significantly correlated with a *RAS* or *NF1* mutation AND no other apparent cause of increased PI3K activity.

ERBB4 Mutation	Table 2A	Table 2B	Table 3	Table 4	Table 5	Figure 4	Rank
R106C	1		1	1	1	1	5
A383T	1			1	1	1	4
S418F	1			1	1	1	4
E452K	1			1	1	1	4
P517A	1			1	1	1	4
R711C		1		1	1	1	4
P759L		1		1	1	1	4
P800L		1		1	1	1	4
D813N		1		1	1	1	4
D861N		1		1	1	1	4
P925S		1		1	1	1	4
G936E		1		1	1	1	4
E969K		1		1	1	1	4
G85S	1			1	1		3
E33K				1	1	1	3
D150N				1	1	1	3
R196C	1			1		1	3
P331S	1			1	1		3
T422I	1			1	1		3
R491K	1			1	1		3
G741E		1	1	1			3
N814T		1		1		1	3
P943S		1		1		1	3
R992C		1		1	1		3
R1142Q				1	1	1	3
P1165L				1	1	1	3
P1276S				1	1	1	3
P1282S				1	1	1	3
P1300S				1	1	1	3
R114Q				1		1	2
G340E	1					1	2
G549S				1	1		2
P572L				1	1		2
F662L					1	1	2
L864P		1	1				2
P1080L				1	1		2
P1117L				1	1		2
R1127K				1	1		2
R1139Q				1	1		2
E1187D					1		1
Total: 40	11	13	3	36	33	26	

Table 7. Prioritization of candidate *ERBB4* driver mutant alleles in the TCGA-SKCM *BRAF* WT melanoma dataset. Columns refer to tables and figures found in the manuscript and the mutations listed in the table are from the values circled in red in those tables and figures.

	Viral titers		Clonogenic proliferation efficiency
	Cell line		Ratios
Virus	C127	MEL-JUSO	MEL-JUSO/C127
Vector	1.28E+07	7.69E+05	6.02%
ERBB4 WT	1.76E+05	4.43E+04	25.20%
ERBB4 R106C	1.89E+05	5.99E+04	31.60%
ERBB4 Y285C	7.68E+05	4.92E+05	64.03%
ERBB4 P759L	4.14E+05	2.56E+05	61.77%

Table 8. In the MEL-JUSO *BRAF* WT melanoma cell line, the *ERBB4* Y285C and P759L mutants cause greater clonogenic proliferation than *ERBB4* WT.

	Cell Proliferation	
	No IL3	**No IL3**
32D Cell Line	**No NRG1beta**	**30 nM NRG1beta**
Vector+Vector	3.0x10^4	3.6x10^4
Vector+ERBB2	3.2x10^4	5.6x10^4
ERBB4+Vector	6.2x10^4	5.4x10^4
ERBB4+ERBB2	5.2x10^4	1.4x10^5

Table 9. The ERBB4 ligand NRG1beta stimulates IL3-independent proliferation of the 32D/ERBB4+ERBB2 cell line, but not any of the control cell lines.

Figures



Figure 1. The extracellular domains of ERBB4 exist in an equilibrium between the closed conformation that has low affinity for ligand and buried dimerization motifs and the open conformation that has high affinity for ligand and has exposed dimerization motifs. Adapted from [9].



Figure 2. ERBB4 ligands stimulate ERBB receptor signaling via ERBB4 homodimerization and heterodimerization. Adapted from [9].



Figure 3 – In *BRAF* WT melanomas of the TCGA-SKCM dataset, *ERBB4* nonsynonymous missense mutant alleles are evenly distributed across the entire *ERBB4* coding region.



Figure 4. Within the 129 *BRAF* WT cases in the TCGA-SKCM dataset which harbor a *RAS* or *NF1* nonsynonymous mutation, an *ERBB4* missense mutation and elevated *ERBB4* transcription appear to be largely mutually exclusive.



Figure 5. The non-random occurrence of *ERBB4* mutations in *BRAF* WT tumors suggests that *ERBB4* mutations drive signaling through the PI3K pathway, thereby enabling ERBB4 signaling to cooperate with *RAS*/*NF1* mutations to drive *BRAF* WT tumors. Adapted from [8].

References

1. *The Surveillance, Epidemiology, and End Results Program of the National Cancer Institute*. [Accessed June 16, 2022]; Available from: https://seer.cancer.gov.
2. *Melanoma of the Skin SEER Relative Survival Rates by Time Since Diagnosis, 2000-2018, Metastatic Tumors*. [Accessed June 16, 2022]; Available from: https://seer.cancer.gov/statistics-network/explorer/application.html?site=53&data_type=4&graph_type=6&compareBy=sex&chk_sex_1=1&race=1&age_range=1&stage=106&advopt_precision=1&advopt_show_ci=on&advopt_display=2.
3. Schummer, P., B. Schilling, and A. Gesierich, *Long-Term Outcomes in BRAF-Mutated Melanoma Treated with Combined Targeted Therapy or Immune Checkpoint Blockade: Are We Approaching a True Cure?* Am J Clin Dermatol, 2020. **21**(4): p. 493-504.
4. Robert, C., et al., *Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.* N Engl J Med, 2019. **381**(7): p. 626-636.
5. Larkin, J., et al., *Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.* N Engl J Med, 2019. **381**(16): p. 1535-1546.
6. Dummer, R., et al., *Rationale for Immune Checkpoint Inhibitors Plus Targeted Therapy in Metastatic Melanoma: A Review.* JAMA Oncol, 2020. **6**(12): p. 1957-1966.
7. Swetter, S.M., et al., *NCCN Guidelines(R) Insights: Melanoma: Cutaneous, Version 2.2021.* J Natl Compr Canc Netw, 2021. **19**(4): p. 364-376.
8. Lucas, L.M., et al., *ERBB4 drives the proliferation of BRAF WT melanoma cell lines.* medRxiv. **Submitted**.
9. Lucas, L.M., et al., *The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein.* Pharmacol Rev, 2022. **74**(1): p. 18-47.
10. Saraon, P., et al., *Receptor tyrosine kinases and cancer: oncogenic mechanisms and therapeutic approaches.* Oncogene, 2021. **40**(24): p. 4079-4093.
11. Tian, X., et al., *Challenge and countermeasures for EGFR targeted therapy in non-small cell lung cancer.* Biochim Biophys Acta Rev Cancer, 2022. **1877**(1): p. 188645.
12. Reita, D., et al., *Molecular Mechanism of EGFR-TKI Resistance in EGFR-Mutated Non-Small Cell Lung Cancer: Application to Biological Diagnostic and Monitoring.* Cancers (Basel), 2021. **13**(19).
13. Tsubata, Y., R. Tanino, and T. Isobe, *Current Therapeutic Strategies and Prospects for EGFR Mutation-Positive Lung Cancer Based on the Mechanisms Underlying Drug Resistance.* Cells, 2021. **10**(11).
14. Di Noia, V., et al., *Treating disease progression with osimertinib in EGFR-mutated non-small-cell lung cancer: novel targeted agents and combination strategies.* ESMO Open, 2021. **6**(6): p. 100280.
15. Zhou, J., Q. Ji, and Q. Li, *Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies.* J Exp Clin Cancer Res, 2021. **40**(1): p. 328.
16. Melosky, B., et al., *The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer.* Ther Adv Med Oncol, 2021. **13**: p. 17588359211056306.

17. Chen, J., M. Colosimo, and E. Lim, *The management of HER2-positive early breast cancer: Current and future therapies.* Asia Pac J Clin Oncol, 2021. **17 Suppl 6**: p. 3-12.
18. Wu, H.X., K.Q. Zhuo, and K. Wang, *Efficacy of targeted therapy in patients with HER2-positive non-small cell lung cancer: A systematic review and meta-analysis.* Br J Clin Pharmacol, 2022. **88**(5): p. 2019-2034.
19. Salkeni, M.A., et al., *Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer.* Breast Cancer (Dove Med Press), 2021. **13**: p. 539-557.
20. You, Z., et al., *Application of HER2 peptide vaccines in patients with breast cancer: a systematic review and meta-analysis.* Cancer Cell Int, 2021. **21**(1): p. 489.
21. Pupa, S.M., et al., *HER2 Signaling and Breast Cancer Stem Cells: The Bridge behind HER2-Positive Breast Cancer Aggressiveness and Therapy Refractoriness.* Cancers (Basel), 2021. **13**(19).
22. Li, L., et al., *Antibody-drug conjugates in HER2-positive breast cancer.* Chin Med J (Engl), 2021. **135**(3): p. 261-267.
23. Hrynchak, I., et al., *Nanobody-Based Theranostic Agents for HER2-Positive Breast Cancer: Radiolabeling Strategies.* Int J Mol Sci, 2021. **22**(19).
24. Fatima, I., et al., *Quantum Dots: Synthesis, Antibody Conjugation, and HER2-Receptor Targeting for Breast Cancer Therapy.* J Funct Biomater, 2021. **12**(4).
25. Azar, I., et al., *Spotlight on Trastuzumab Deruxtecan (DS-8201,T-DXd) for HER2 Mutation Positive Non-Small Cell Lung Cancer.* Lung Cancer (Auckl), 2021. **12**: p. 103-114.
26. Vathiotis, I.A., et al., *HER2 Aberrations in Non-Small Cell Lung Cancer: From Pathophysiology to Targeted Therapy.* Pharmaceuticals (Basel), 2021. **14**(12).
27. Hafeez, U., et al., *New insights into ErbB3 function and therapeutic targeting in cancer.* Expert Rev Anticancer Ther, 2020. **20**(12): p. 1057-1074.
28. Kiavue, N., et al., *ERBB3 mutations in cancer: biological aspects, prevalence and therapeutics.* Oncogene, 2020. **39**(3): p. 487-502.
29. Riese, D.J., 2nd, R.M. Gallo, and J. Settleman, *Mutational activation of ErbB family receptor tyrosine kinases: insights into mechanisms of signal transduction and tumorigenesis.* Bioessays, 2007. **29**(6): p. 558-65.
30. *NCI GDC Data Portal: TCGA-SKCM Skin Cutaneous Melanoma Data Set*. [Accessed June 15, 2022]; Available from: https://portal.gdc.cancer.gov/projects/TCGA-SKCM.
31. Kryazhimskiy, S. and J.B. Plotkin, *The population genetics of dN/dS.* PLoS Genet, 2008. **4**(12): p. e1000304.
32. Van den Eynden, J. and E. Larsson, *Mutational Signatures Are Critical for Proper Estimation of Purifying Selection Pressures in Cancer Somatic Mutation Data When Using the dN/dS Metric.* Front Genet, 2017. **8**: p. 74.
33. Wilson, K.J., et al., *Functional selectivity of EGF family peptide growth factors: implications for cancer.* Pharmacol Ther, 2009. **122**(1): p. 1-8.
34. Wilson, K.J., et al., *The Q43L mutant of neuregulin 2beta is a pan-ErbB receptor antagonist.* Biochem J, 2012. **443**(1): p. 133-44.
35. Prickett, T.D., et al., *Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.* Nat Genet, 2009. **41**(10): p. 1127-32.
36. Al Mahi, A. and J. Ablain, *RAS pathway regulation in melanoma.* Dis Model Mech, 2022. **15**(2).

37. Liu, C.Y., et al., *Molecular target therapeutics of EGF-TKI and downstream signaling pathways in non-small cell lung cancers.* J Chin Med Assoc, 2022. **85**(4): p. 409-413.
38. Smith, C.I.E. and J.A. Burger, *Resistance Mutations to BTK Inhibitors Originate From the NF-kappaB but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway.* Front Immunol, 2021. **12**: p. 689472.
39. Huang, X.L., et al., *Role of receptor tyrosine kinases mediated signal transduction pathways in tumor growth and angiogenesis-New insight and futuristic vision.* Int J Biol Macromol, 2021. **180**: p. 739-752.
40. Oliveres, H., D. Pesantez, and J. Maurel, *Lessons to Learn for Adequate Targeted Therapy Development in Metastatic Colorectal Cancer Patients.* Int J Mol Sci, 2021. **22**(9).
41. Santos, E.D.S., et al., *EGFR targeting for cancer therapy: Pharmacology and immunoconjugates with drugs and nanoparticles.* Int J Pharm, 2021. **592**: p. 120082.
42. Zhao, Y., H. Wang, and C. He, *Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation: from mechanism analysis to clinical strategy.* J Cancer Res Clin Oncol, 2021. **147**(12): p. 3653-3664.
43. Barbosa, R., L.A. Acevedo, and R. Marmorstein, *The MEK/ERK Network as a Therapeutic Target in Human Cancer.* Mol Cancer Res, 2021. **19**(3): p. 361-374.
44. Kurppa, K.J., et al., *Activating ERBB4 mutations in non-small cell lung cancer.* Oncogene, 2016. **35**(10): p. 1283-91.
45. Riese, D.J., 2nd, et al., *The cellular response to neuregulins is governed by complex interactions of the erbB receptor family.* Mol Cell Biol, 1995. **15**(10): p. 5770-6.
46. Wilson, K.J., et al., *EGFR ligands exhibit functional differences in models of paracrine and autocrine signaling.* Growth Factors, 2012. **30**(2): p. 107-16.
47. *NCI GDC Data Portal: TCGA-SKCM Skin Cutaneous Melanoma Data Set*. June 15, 2022]; Available from: https://portal.gdc.cancer.gov/projects/TCGA-SKCM.
48. *NCI Genomic Data Commons (GDC) Portal*. June 15, 2022]; Available from: https://portal.gdc.cancer.gov/.
49. *The R Project for Statistical Computing*. June 15, 2022]; Available from: https://www.r-project.org.
50. *GraphPad Prism*. June 15, 2022]; Available from: https://www.graphpad.com.
51. Riese, D.J., 2nd and D. DiMaio, *An intact PDGF signaling pathway is required for efficient growth transformation of mouse C127 cells by the bovine papillomavirus E5 protein.* Oncogene, 1995. **10**(7): p. 1431-9.
52. *MEL-JUSO - DSMZ # ACC 74*. June 15, 2022]; Available from: https://www.dsmz.de/collection/catalogue/details/culture/ACC-74.
53. *DSMZ*. June 15, 2022]; Available from: https://www.dsmz.de.
54. Gilmore, J.L., R.M. Gallo, and D.J. Riese, 2nd, *The epidermal growth factor receptor (EGFR)-S442F mutant displays increased affinity for neuregulin-2beta and agonist-independent coupling with downstream signalling events.* Biochem J, 2006. **396**(1): p. 79-88.
55. *Cytiva*. June 15, 2022]; Available from: https://www.cytivalifesciences.com/en/us/shop.
56. *Corning*. June 15, 2022]; Available from: https://www.corning.com/worldwide/en/products/life-sciences.html.

57. *Broad Institute Cancer Cell Line Encyclopedia*. June 15, 2022]; Available from: https://sites.broadinstitute.org/ccle/.
58. Williams, E.E., et al., *A constitutively active ErbB4 mutant inhibits drug-resistant colony formation by the DU-145 and PC-3 human prostate tumor cell lines.* Cancer Lett, 2003. **192**(1): p. 67-74.
59. Miller, A.D. and G.J. Rosman, *Improved retroviral vectors for gene transfer and expression.* Biotechniques, 1989. **7**(9): p. 980-2, 984-6, 989-90.